www.EquityMarketsInc.com announced its research report highlighting Keryx Biopharmaceuticals (NASDAQ: KERX) and AEterna Zentaris Inc. (USA) (NASDAQ: AEZS). The research is available with sign-up at:
View the full KERX chart at Wikinvest
KERX has been under pressure since their announcement Monday on:
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex (Ferric Citrate) Phase 3 Long-Term Study - Study being conducted pursuant to Special Protocol Assessment with the Food and Drug Administration
VFC Stock House @ Seeking Alpha has an updated view on the recent events at KERX and he states:
"While this week's Zerenex update is a noteworthy milestone, by the time the long term Phase III is wrapped up, investors will most likely have a better idea of where the company stands in terms of a partnership or acquisition. In the meantime, KERX could move higher over the next few months leading into trial results and on takeover speculation."
ProActive Capital Indexes
See ProActive's Disclaimer